vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and INGLES MARKETS INC (IMKTA). Click either name above to swap in a different company.

INGLES MARKETS INC is the larger business by last-quarter revenue ($1.4B vs $950.5M, roughly 1.4× Astrana Health, Inc.). INGLES MARKETS INC runs the higher net margin — 2.0% vs 0.7%, a 1.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 6.6%). INGLES MARKETS INC produced more free cash flow last quarter ($2.1M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 0.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Ingles Markets, Inc. is an American supermarket chain based in Black Mountain, North Carolina. As of September 2021, the company operates 198 supermarkets in the Appalachian region of the Southeastern United States. The company is listed on the NASDAQ under the ticker symbol IMKTA and is part of the Global Select Market tier of trading.

ASTH vs IMKTA — Head-to-Head

Bigger by revenue
IMKTA
IMKTA
1.4× larger
IMKTA
$1.4B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+36.3% gap
ASTH
42.9%
6.6%
IMKTA
Higher net margin
IMKTA
IMKTA
1.4% more per $
IMKTA
2.0%
0.7%
ASTH
More free cash flow
IMKTA
IMKTA
$8.0M more FCF
IMKTA
$2.1M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
0.2%
IMKTA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASTH
ASTH
IMKTA
IMKTA
Revenue
$950.5M
$1.4B
Net Profit
$6.6M
$28.1M
Gross Margin
24.4%
Operating Margin
1.9%
2.9%
Net Margin
0.7%
2.0%
Revenue YoY
42.9%
6.6%
Net Profit YoY
184.4%
69.6%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$950.5M
$1.4B
Q3 25
$956.0M
$1.4B
Q2 25
$654.8M
$1.3B
Q1 25
$620.4M
$1.3B
Q4 24
$665.2M
$1.3B
Q3 24
$478.7M
$1.4B
Q2 24
$486.3M
$1.4B
Q1 24
$404.4M
$1.4B
Net Profit
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$6.6M
$28.1M
Q3 25
$373.0K
$25.7M
Q2 25
$9.4M
$26.2M
Q1 25
$6.7M
$15.1M
Q4 24
$-7.8M
$16.6M
Q3 24
$16.1M
$-1.5M
Q2 24
$19.2M
$31.7M
Q1 24
$14.8M
$31.9M
Gross Margin
ASTH
ASTH
IMKTA
IMKTA
Q4 25
24.4%
Q3 25
24.5%
Q2 25
24.3%
Q1 25
23.4%
Q4 24
23.4%
Q3 24
21.4%
Q2 24
23.7%
Q1 24
23.5%
Operating Margin
ASTH
ASTH
IMKTA
IMKTA
Q4 25
1.9%
2.9%
Q3 25
2.0%
2.6%
Q2 25
3.1%
2.8%
Q1 25
3.3%
1.6%
Q4 24
0.1%
1.8%
Q3 24
5.9%
-0.1%
Q2 24
6.2%
3.2%
Q1 24
7.5%
3.3%
Net Margin
ASTH
ASTH
IMKTA
IMKTA
Q4 25
0.7%
2.0%
Q3 25
0.0%
1.9%
Q2 25
1.4%
1.9%
Q1 25
1.1%
1.1%
Q4 24
-1.2%
1.3%
Q3 24
3.4%
-0.1%
Q2 24
3.9%
2.3%
Q1 24
3.7%
2.3%
EPS (diluted)
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
IMKTA
IMKTA
Cash + ST InvestmentsLiquidity on hand
$429.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$1.6B
Total Assets
$2.2B
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Total Debt
ASTH
ASTH
IMKTA
IMKTA
Q4 25
Q3 25
$514.8M
Q2 25
Q1 25
Q4 24
Q3 24
$532.6M
Q2 24
Q1 24
Stockholders' Equity
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$779.3M
$1.6B
Q3 25
$775.5M
$1.6B
Q2 25
$765.5M
$1.6B
Q1 25
$745.4M
$1.6B
Q4 24
$712.7M
$1.6B
Q3 24
$704.6M
$1.5B
Q2 24
$678.9M
$1.6B
Q1 24
$653.5M
$1.5B
Total Assets
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$2.2B
$2.6B
Q3 25
$2.2B
$2.6B
Q2 25
$1.4B
$2.5B
Q1 25
$1.3B
$2.5B
Q4 24
$1.4B
$2.5B
Q3 24
$1.3B
$2.5B
Q2 24
$1.3B
$2.5B
Q1 24
$1.2B
$2.5B
Debt / Equity
ASTH
ASTH
IMKTA
IMKTA
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
0.34×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
IMKTA
IMKTA
Operating Cash FlowLast quarter
$-2.9M
$38.4M
Free Cash FlowOCF − Capex
$-6.0M
$2.1M
FCF MarginFCF / Revenue
-0.6%
0.1%
Capex IntensityCapex / Revenue
0.3%
2.6%
Cash ConversionOCF / Net Profit
-0.44×
1.37×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$123.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$-2.9M
$38.4M
Q3 25
$10.0M
$59.9M
Q2 25
$90.9M
$74.8M
Q1 25
$16.6M
$63.1M
Q4 24
$-10.9M
$-43.6M
Q3 24
$34.0M
$73.3M
Q2 24
$23.2M
$103.3M
Q1 24
$6.0M
$70.4M
Free Cash Flow
ASTH
ASTH
IMKTA
IMKTA
Q4 25
$-6.0M
$2.1M
Q3 25
$7.4M
$36.8M
Q2 25
$89.5M
$45.4M
Q1 25
$13.6M
$38.9M
Q4 24
$-13.5M
$-81.4M
Q3 24
$31.7M
$5.4M
Q2 24
$20.4M
$58.6M
Q1 24
$5.6M
$35.3M
FCF Margin
ASTH
ASTH
IMKTA
IMKTA
Q4 25
-0.6%
0.1%
Q3 25
0.8%
2.7%
Q2 25
13.7%
3.4%
Q1 25
2.2%
2.9%
Q4 24
-2.0%
-6.3%
Q3 24
6.6%
0.4%
Q2 24
4.2%
4.2%
Q1 24
1.4%
2.6%
Capex Intensity
ASTH
ASTH
IMKTA
IMKTA
Q4 25
0.3%
2.6%
Q3 25
0.3%
1.7%
Q2 25
0.2%
2.2%
Q1 25
0.5%
1.8%
Q4 24
0.4%
2.9%
Q3 24
0.5%
4.9%
Q2 24
0.6%
3.2%
Q1 24
0.1%
2.6%
Cash Conversion
ASTH
ASTH
IMKTA
IMKTA
Q4 25
-0.44×
1.37×
Q3 25
26.69×
2.33×
Q2 25
9.65×
2.85×
Q1 25
2.48×
4.17×
Q4 24
-2.63×
Q3 24
2.11×
Q2 24
1.21×
3.26×
Q1 24
0.40×
2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

IMKTA
IMKTA

Grocery$502.1M37%
Perishables$359.7M26%
Non Foods$305.5M22%
Gasoline$152.1M11%
Other$53.6M4%

Related Comparisons